At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
IVIEW-1201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-Center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW 1201 Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis
In Brief
A Phase 2 clinical trial evaluating IVIEW-1201 and Ofloxacin Eye Drops for Acute Bacterial Conjunctivitis. Completed, enrolled 129 participants across 1 site.
Detailed Summary
A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Bacterial Conjunctivitis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedApr 2023
Primary CompletionNov 2023
Study CompletionOct 2024
TodayJul 2026
First PostedApr 18, 2023
Enrollment StartJan 5, 2023
Primary CompletionNov 13, 2023
Study CompletionOct 12, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.2 years ago
Interventions
IVIEW-1201drug
Four times per day for day 1-2 and three times per day for day 3-7
Ofloxacin Eye Dropsdrug
Four times per day for day 1-2 and three times per day for day 3-7